×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AQST – aquestive therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AQST
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/4
08:27 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Trimmed Their Revenue Forecasts By 26% [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Trimmed Their Revenue Forecasts By 26% [Yahoo! Finance]
2/3
08:13 pm
aqst
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Low
Report
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
2/3
01:39 pm
aqst
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
2/3
10:46 am
aqst
Leerink sees ‘silver lining' in Aquestive CRL given defined path to approval [Yahoo! Finance]
Low
Report
Leerink sees ‘silver lining' in Aquestive CRL given defined path to approval [Yahoo! Finance]
2/3
10:13 am
aqst
Aquestive Therapeutics (NASDAQ:AQST) was given a new $6.00 price target on by analysts at Lake Street Capital.
Medium
Report
Aquestive Therapeutics (NASDAQ:AQST) was given a new $6.00 price target on by analysts at Lake Street Capital.
2/3
06:32 am
aqst
Aquestive receives FDA CRL for Anaphylm allergic reaction treatment [Yahoo! Finance]
Low
Report
Aquestive receives FDA CRL for Anaphylm allergic reaction treatment [Yahoo! Finance]
2/2
03:55 pm
aqst
Aquestive jumps despite receiving FDA Complete Response Letter [Seeking Alpha]
Neutral
Report
Aquestive jumps despite receiving FDA Complete Response Letter [Seeking Alpha]
2/2
01:24 pm
aqst
AQST Investors Have Opportunity to Join Aquestive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Medium
Report
AQST Investors Have Opportunity to Join Aquestive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
04:01 pm
aqst
aquestive therapeutics, inc.
MISS
Report
2.2%
aquestive therapeutics, inc.
8/11/2025
04:01 pm
aqst
aquestive therapeutics, inc.
BEAT
Report
2.8%
aquestive therapeutics, inc.
5/12/2025
04:01 pm
aqst
aquestive therapeutics, inc.
MISS
Report
-19.6%
aquestive therapeutics, inc.
3/5/2025
04:01 pm
aqst
aquestive therapeutics, inc.
MISS
Report
-7.5%
aquestive therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/2
07:04 am
aqst
Form 8-K Aquestive Therapeutics, For: Jan 30
High
Report
Form 8-K Aquestive Therapeutics, For: Jan 30
1/21
04:46 pm
aqst
Form S-8 Aquestive Therapeutics,
Low
Report
Form S-8 Aquestive Therapeutics,
1/9
07:19 am
aqst
Form 8-K Aquestive Therapeutics, For: Jan 09
High
Report
Form 8-K Aquestive Therapeutics, For: Jan 09
12/5
01:06 pm
aqst
Form 4 Aquestive Therapeutics, For: Dec 04 Filed by: Boyd Peter E.
Low
Report
Form 4 Aquestive Therapeutics, For: Dec 04 Filed by: Boyd Peter E.
12/4
10:40 am
aqst
Form 4 Aquestive Therapeutics, For: Dec 02 Filed by: Cioffi Melina
Low
Report
Form 4 Aquestive Therapeutics, For: Dec 02 Filed by: Cioffi Melina
11/17
04:40 pm
aqst
Form 144 Aquestive Therapeutics, Filed by: Kraus Carl N
Medium
Report
Form 144 Aquestive Therapeutics, Filed by: Kraus Carl N
11/14
08:24 am
aqst
Form SCHEDULE 13G Aquestive Therapeutics, Filed by: RTW INVESTMENTS, LP
Medium
Report
Form SCHEDULE 13G Aquestive Therapeutics, Filed by: RTW INVESTMENTS, LP
11/12
09:36 am
aqst
Form 4 Aquestive Therapeutics, For: Nov 10 Filed by: Davis Matthew W.
Low
Report
Form 4 Aquestive Therapeutics, For: Nov 10 Filed by: Davis Matthew W.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/5
Form 8-K Aquestive Therapeutics, For: Nov 05
23.6%
4/24 Form 8-K Aquestive Therapeutics, For: Apr 23 17.2%
2/10 Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film 17.0%
12/10 Form 424B5 Aquestive Therapeutics, 16.5%
4/5 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. 14.7%
8/6 Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study 11.7%
11/9 Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.8%
3/3 Form 4 Aquestive Therapeutics, For: Feb 29 Filed by: Kendall Keith J 10.7%
3/18 Form 4 Aquestive Therapeutics, For: Mar 16 Filed by: Boyd Peter E. 10.7%
7/2 Form 4 Aquestive Therapeutics, For: Jun 30 Filed by: Schobel Alexander Mark 8.3%
4/24 Form 8-K Aquestive Therapeutics, For: Apr 23 17.2%
2/10 Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film 17.0%
12/10 Form 424B5 Aquestive Therapeutics, 16.5%
4/5 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. 14.7%
8/6 Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study 11.7%
11/9 Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.8%
3/3 Form 4 Aquestive Therapeutics, For: Feb 29 Filed by: Kendall Keith J 10.7%
3/18 Form 4 Aquestive Therapeutics, For: Mar 16 Filed by: Boyd Peter E. 10.7%
7/2 Form 4 Aquestive Therapeutics, For: Jun 30 Filed by: Schobel Alexander Mark 8.3%
TOP News Decliners
3/11
Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.450 ActVsEst (0.030) - Miss
-40.0%
1/12 Aquestive Therapeutics Receives FDA Response to Citizen’s Petition -33.9%
12/12 Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock -19.7%
5/8 Q1/2019 3/31/2019 EPS -0.590 ZacksConsensus -0.490 ActVsEst (0.100) - Miss -17.1%
3/12 Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call Transcript [The Motley Fool] -13.8%
3/15 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. -13.0%
2/26 Form 4/A Aquestive Therapeutics, For: Nov 30 Filed by: Kendall Keith J -10.6%
12/27 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Lake Street Capital. They now have a $10.00 price target on the stock, down previously from $11.00. -9.9%
8/13 Form 4 Aquestive Therapeutics, For: Aug 09 Filed by: Wood Theresa -9.7%
5/20 Aquestive Therapeutics Inc (NASDAQ: AQST) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating. -9.3%
1/12 Aquestive Therapeutics Receives FDA Response to Citizen’s Petition -33.9%
12/12 Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock -19.7%
5/8 Q1/2019 3/31/2019 EPS -0.590 ZacksConsensus -0.490 ActVsEst (0.100) - Miss -17.1%
3/12 Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call Transcript [The Motley Fool] -13.8%
3/15 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. -13.0%
2/26 Form 4/A Aquestive Therapeutics, For: Nov 30 Filed by: Kendall Keith J -10.6%
12/27 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Lake Street Capital. They now have a $10.00 price target on the stock, down previously from $11.00. -9.9%
8/13 Form 4 Aquestive Therapeutics, For: Aug 09 Filed by: Wood Theresa -9.7%
5/20 Aquestive Therapeutics Inc (NASDAQ: AQST) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating. -9.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: